等待开盘 05-11 09:30:00 美东时间
+0.350
+0.27%
Celcuity stock rises after Phase 3 VIKTORIA-1 trial meets endpoint, showing PFS gains in breast cancer and setting up FDA filing.
05-04 19:05
FDA accepts NDA for Celcuity's advanced breast cancer therapy. Analyst downgrades stock due to high valuation. Next catalyst is topline data.
2025-11-17 23:13
Celcuity (NASDAQ:CELC) will release its quarterly earnings report on Wednesday,...
2025-11-11 22:03
10:21 AM EDT, 08/26/2024 (MT Newswires) -- Celcuity (CELC) has an average rating of Buy and price targets ranging from $23 to $39, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and E...
2024-08-26 22:21
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $27 price target.
2024-08-15 19:54